IPO-38 is identified as a novel serum biomarker of gastric cancer based on clinical proteomics technology.


Gastric cancer is one of the most common malignancies in China. So far, there are few reliable serum biomarkers for diagnosis. The available biomarkers of CEA, CA19-9 and CA72-4 are not sufficiently sensitive and specific for gastric cancer. In this study, a high density antibody microarray was used for identifying new biomarkers from serum samples of… (More)
DOI: 10.1021/pr700638k


14 Figures and Tables